Atrium Therapeutics amends 8-K to fix share count after PIPE offering
The company corrected a filing error about total shares outstanding following its October 7, 2026 private placement, while leaving all other disclosures unchanged.
Atrium Therapeutics, Inc. filed a Form 8-K/A on October 9, 2026 to amend a current report originally filed October 8, 2026. The amendment was filed to correct the previously disclosed number of shares outstanding after the offering.1 The company stated that no other information in the original filing had been revised.1
As previously disclosed, on October 7, 2026 the company entered into a securities purchase agreement with selected accredited investors under Rule 501(a) of Regulation D, agreeing to sell an aggregate of 5,170,384 shares of common stock along with pre-funded warrants to purchase up to 1,134,930 additional shares.1
With the corrected figures, Atrium said it will have 21,571,507 shares of common stock outstanding after the offering closes, a total that accounts for shares tied to make whole equity awards granted in connection with the company's spin-off from Avidity Biosciences, Inc.1
The filing included standard forward-looking statement language, noting that actual results could differ from expectations due to risks including the possibility that the company or the PIPE investors fail to satisfy closing conditions, uncertainty over the timing of the offering's close, and other risks detailed in the company's Form 10-Q filings for the quarters ended March 31, 2026 and June 30, 2026, as well as in future SEC filings.1
The report was signed by Chief Executive Officer Kathleen Gallagher on October 9, 2026. Atrium Therapeutics trades on the Nasdaq Global Select Market under the ticker RNA.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.